Responsible use of 7-OH.

Dose ranges in self-report data

Published self-report studies of kratom users [8, 9] report a wide dose range that has shifted as concentrated 7-OH products entered the market. The Smith et al. 2021 community-survey study found self-reported daily totals of mitragynine equivalents ranging across two orders of magnitude. For concentrated 7-OH products specifically, single-tablet doses on the market range from 5mg to 100mg per unit; pack sizes range from 1 tablet to 100 tablets.

Translating those numbers into "safe" doses is not something we'll do. Individual response varies dramatically by tolerance state, body mass, hepatic enzyme activity, and concurrent substances. We cite the data; the rest is between you and a clinician.

Tolerance development

Tolerance to μ-opioid agonists, including 7-OH, develops rapidly with regular dosing — typically within days to weeks for many users. The pharmacological mechanism (receptor desensitization, β-arrestin recruitment, downstream signaling adaptation) is well-characterized for other opioids and is reasonable to extrapolate to 7-OH given its receptor pharmacology. Practical implication in self-report data: users describe needing 2-3x starting doses within 1-2 months of daily use to achieve equivalent subjective effects.

Use patterns the literature documents

Garcia-Romeu et al. 2020 [9] and Smith et al. 2021 [8] both identify distinct kratom-use phenotypes: occasional use for pain or fatigue, daily moderate use, and escalating daily use trending toward dependence. Concentrated 7-OH appears to compress the timeline between these stages compared to leaf-based products, based on early case-report data, though formal longitudinal research on 7-OH specifically is limited.

What about "harm-reduction" framing?

Some users describe 7-OH as a harm-reduction substitute when transitioning off heavier opioids. Published peer-reviewed data on this use is limited; some clinicians and case reports describe successful outcomes in supervised contexts, others document cases of dependence transfer rather than recovery. We don't take a position. If you're considering this use, talk to a clinician familiar with opioid use disorder treatment.

If dependence has developed

See research on 7-OH dependence and discontinuation and medications studied for kratom-related discontinuation. Crisis resources at /GetHelp.

References

Numbered citations link to our bibliography.